Help us do something about it.

FDA’s reclassification of Dessicated Thyroid Extract (DTE) as a biologic is unnecessary, scientifically flawed, and demonstrably harmful to patients. It strips away choice, likely increases prices, and hands control of a critical therapy to a single drugmaker.

• DTE has been prescribed and used safely for more than a hundred years to treat millions of Americans with hypothyroidism. Patients depend on it when synthetic options don’t work for them.
• Now, those patients will be left without a vital therapy.

We must push back against this unnecessary overreach by FDA so that patients are not collateral damage in a policy change that in effect clears the field to create a monopoly for one drugmaker.

Tell FDA to:

• Keep DTE regulated as a small-molecule drug, consistent with science and decades of precedent.
• Reject a monopoly-driven reclassification that limits treatment options and drives up prices for patients.
• Protect patient/provider decision-making by preserving access to DTE alongside synthetic alternatives.

The implications are serious for patients who rely on this therapy.